Combination of OBP-301 and Pembrolizumab for Advanced Esophagogastric Cancer
Phase II Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in PD-L1-Negative or Immunotherapy-refractory Esophagogastric Adenocarcinoma
This study is trying a new treatment combining OBP-301 and pembrolizumab to see if it can help people with advanced esophageal and gastric cancer who haven't responded well to previous immunotherapy.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 27 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Weill Medical College of Cornell University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation, pembrolizumab |
| Locations | 2 sites (New York, New York and 1 other locations) |
| Trial ID | NCT06340711 on ClinicalTrials.gov |
What this trial studies
This study investigates the safety and effectiveness of the investigational drug OBP-301 in combination with pembrolizumab for patients with advanced or metastatic esophageal and gastric adenocarcinoma who have previously undergone immunotherapy. Participants will receive OBP-301 injections directly into their tumors every two weeks, alongside pembrolizumab infusions every six weeks. The primary goal is to determine the objective response rate, with a target of 20%, and to assess the duration of response and progression-free survival. This approach aims to overcome resistance to prior immunotherapy treatments.
Who should consider this trial
Good fit: Ideal candidates are patients with advanced or metastatic gastric or esophageal adenocarcinoma that is PD-L1 positive and HER2 negative, who have previously received immunotherapy.
Not a fit: Patients with active autoimmune diseases requiring systemic treatment or those currently participating in other studies may not benefit from this trial.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced esophagogastric adenocarcinoma who have not responded to previous immunotherapy.
How similar studies have performed: Previous trials combining OBP-301 with pembrolizumab have shown promising results, indicating potential effectiveness in similar patient populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically or cytologically confirmed advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma amenable to intra-tumoral injection (i.e. at least 1 cm in size) * Tumor must be examined forPD-L1 assessment as defined by a Combined Positive Score (CPS), and approved commercial diagnostic assay * If the PD-L1 CPS score is \> 1, patients must have received at least one line of systemic therapy for advanced disease that includes a PD-1 or PD-L1 inhibitor. 1. Patients must have clinical or radiographic disease progression on 1L therapy, or within three months of the last dose of immunotherapy 2. Patients must be eligible for immunotherapy (i.e. have not had a Grade 3 or 4 immunotherapy related gastrointestinal or pulmonary toxicity, or other immune-related adverse event that excludes them from receiving future immunotherapy per PI discretion) * If the PD-L1 CPS score is \< 1, patients must not have received prior anti-PD-1 or PD-L1 therapy and must have received at least one line of systemic therapy for advanced disease. Exclusion Criteria: * Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy within 3 weeks of study Day 1. * Has an active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid) * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (greater than equivalent of 20 mg/day) or any other form of immunosuppressive therapy within 7 days prior to study Day 1. * Has known active central nervous system metastases and/or carcinomatous meningitis. * Has had prior anti-cancer monoclonal antibody chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1, who has not recovered from adverse events due to a previously administered agent. * Has a known additional malignancy within 3 years before the first OBP-301 administration that is progressing or requires active treatment, with the exception of prostate cancer controlled with androgen deprivation therapy. * Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed. * Is known to have acute or chronic active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) * Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. * Has an active infection requiring systemic therapy within 2 weeks of Day 1. * Is unable to comply with protocol procedures * Previous severe hypersensitivity (≥ Grade 3) to any monoclonal antibody * Has not adequately recovered from major surgery or has ongoing surgical complications. * Has had an allogenic tissue/solid organ transplant * Has certain uncontrolled illnesses * Is pregnant or breastfeeding or planning to become pregnant or start breast feeding during the study time period * Is expecting to get someone else pregnant during the study time period
Where this trial is running
New York, New York and 1 other locations
- Weill Cornell Medicine/NewYork-Presbyterian Hospital — New York, New York, United States (Recruiting)
- Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Manish Shah, M.D. — Weill Medical College of Cornell University
- Study coordinator: Casey Owens
- Email: cdo4001@med.cornell.edu
- Phone: 646-962-6046
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.